Insider Transactions in Q4 2021 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2021
|
Xiaobin Wu President, COO & GM China |
BUY
Grant, award, or other acquisition
|
Indirect |
0
|
$0
$30.13 P/Share
|
|
Dec 15
2021
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Indirect |
0
|
$0
$30.13 P/Share
|
|
Dec 14
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-48.7%
|
$418,500
$279.11 P/Share
|
|
Dec 14
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|
|
Dec 01
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,049
-75.26%
|
$376,591
$359.89 P/Share
|
|
Nov 30
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
1,049
+50.0%
|
-
|
|
Nov 30
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
14,820
+8.47%
|
-
|
|
Nov 17
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-27.13%
|
$571,500
$381.37 P/Share
|
|
Nov 17
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|
|
Nov 09
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
2,334
-37.82%
|
$858,912
$368.03 P/Share
|
|
Nov 08
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
7,666
-19.15%
|
$2,690,766
$351.79 P/Share
|
|
Nov 08
2021
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
9,000
-26.41%
|
$3,150,000
$350.8 P/Share
|
|
Oct 31
2021
|
Lai Wang Global Head of R&D |
BUY
Bona fide gift
|
Indirect |
58,188
+50.0%
|
-
|
|
Oct 31
2021
|
Lai Wang Global Head of R&D |
SELL
Bona fide gift
|
Indirect |
58,188
-100.0%
|
-
|
|
Oct 19
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-41.36%
|
$558,000
$372.39 P/Share
|
|
Oct 19
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$178,500
$119.96 P/Share
|